HIV Drug Potentially Tied To Liver Damage

Law360, New York (March 13, 2008, 12:00 AM EDT) -- Trying to cover all the bases, the U.S. Food and Drug Administration and a unit of Johnson & Johnson have reportedly joined forces to issue a new warning regarding a potential link between liver damage and the HIV drug Prezista.

On Thursday, a so-called "dear healthcare professional" letter appeared on the FDA Web site from J&J unit Tibotec Therapeutics, alerting the medical community to a spate of liver injuries and deaths connected to the medication.

"Post-marketing cases of liver injury, including some fatalities, have been reported,"...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.